96 Tests PN: B111389

Components:

45x Ab-conjugated beads (S4P4 - human IFNβ Ab-bead). PN: B111389A. One vial containing 100 µL of anti-human IFNβ conjugated to AimPlex Bead S4P4.

25x Biotin-detection Ab (human IFNβ Biotin-dAb). PN: B111389B. One vial containing 100 µL of biotinylated anti-human IFNβ.

Lyophilized Standard Mix-Human Group 4 Panel B, 10-Plex. PN: HG40010. One vial containing lyophilized recombinant human GASP-1, IFNβ, ANGPT-1, Insulin, Leptin, MIF, Resistin, Survivin, TGFα, and TPO.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human IFNβ.  Can be multiplexed with other analytes in Human Group 4.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 2 pg/mL

  • Quantitation range:

  • LLOQ: < 5 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 4: Negligible

  • Sample volume: 15 µL/test

Description:

Interferon-beta (Accession P01574) is one isoform of type I interferon. It is secreted by many types of cells including macrophages, fibroblasts, and osteoblasts. Recombinant interferon beta potentially has therapeutic abilities in treating chronic hepatitis B, when given intramuscularly. It is also used for treating patients with relapsing-remitting multiple sclerosis to reduce the frequency of relapses and slow the progression of MS. In patients with neuromyelitis optica, however, IFN-β is ineffective and may actually cause harm. The mechanism that results in such different reactions for such similar diseases, is unclear.

References:

  1. Capalbo M, et al. Treatment of chronic hepatitis B with beta interferon given intramuscularly: a pilot study. Ital J Gastroenterol. 1992; 24(4): 203-5. PMID: 1600196.

  2. Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology. 2011; 76(1). Doi: 10.1212/WNL.0b013e318205051d.

  3. Kim S, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Multiple Sclerosis Journal. 2012; 18(10): 1480-83. Doi: 10.1177/1352458512439439.